Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:

NCT ID: NCT02848300 Completed - Clinical trials for Androgenetic Alopecia

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

NCT ID: NCT02791243 Completed - Clinical trials for Androgenetic Alopecia

Photosensitization Study in Androgenetic Alopecia

Start date: April 2016
Phase: Phase 1
Study type: Interventional

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)

NCT ID: NCT02729415 Recruiting - Clinical trials for Androgenetic Alopecia

Point-of-Care Adipose-derived Cells for Hair Growth

ASVF-2016
Start date: October 2016
Phase: Phase 0
Study type: Interventional

Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50. The percentage of men and women affected over the age of 70 increases to 80% and 60% of Caucasian men and women, respectively. Although alopecia is considered a minor dermatologic condition, it is seen as a serious condition with major life consequences by those with alopecia and has been associated with increased incidence of myocardial infarction, hypertension and hypercholesterolaemia. Androgenetic alopecia is associated with feelings of anxiety, depression and various personality disorders among men and women due to physical appearance. Depression, anxiety, aggressiveness, impaired quality of life and social inadequacy have been documented. The presence of alopecia in women is particularly stressful. ADSCs (Adipose Derived Stromal Cells), also called Stromal Vascular Fraction (SVF) cells, include regenerative cell populations derived from adipose tissue and thus are potentially important to multiple disease processes and therapeutic applications for the repair and regeneration of acute and chronically damaged tissues. It has been postulated that SVF cells may promote hair regeneration by increasing the hair-inducing ability of dermal papillae (DP) cells. The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.

NCT ID: NCT02626780 Active, not recruiting - Clinical trials for Androgenetic Alopecia

Adipose-derived SVF for Treatment of Alopecia

Start date: December 2015
Phase: N/A
Study type: Interventional

The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.

NCT ID: NCT02591355 Not yet recruiting - Clinical trials for Androgenetic Alopecia

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

Start date: November 2016
Phase: N/A
Study type: Interventional

Platelet rich plasma (PRP) therapy is a novel therapeutic modality that has seen broad applications for a number of medical indications including those in orthopedics, dentistry, and dermatology. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss, but to the best of our knowledge, there has been only one published case series documenting its use for this indication.

NCT ID: NCT02548689 Recruiting - Clinical trials for Androgenetic Alopecia

PAI-1 Expression in Non-scarring Hair Loss

Start date: July 2015
Phase: N/A
Study type: Observational

This study will investigate whether subjects who suffer from hair loss have increased levels of PAI-1 compared to age-matched control subjects. The level of PAI-1 expression will be determined in subjects without hair loss and in subjects with non-scarring hair loss, including androgenetic alopecia, telogen effluvium and alopecia areata.

NCT ID: NCT02528552 Active, not recruiting - Clinical trials for Androgenetic Alopecia

Treatment of Androgenetic Alopecia in Males With Theradomeā„¢ LH80 PRO

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized double-blind, multi-center study to evaluate the efficacy of low level laser therapy over-the-counter at home device Theradome LH80 PRO, compared to SHAM for promoting hair growth in males diagnosed with androgenetic alopecia, and a usability study to assess subject ability to self-assess hair loss and understanding use of the device.

NCT ID: NCT02503137 Completed - Clinical trials for Androgenetic Alopecia

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.

NCT ID: NCT02486848 Not yet recruiting - Clinical trials for Androgenetic Alopecia

Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil

Start date: June 2016
Phase: N/A
Study type: Interventional

5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low i.e., 30-40% re-grow hair. The primary purpose of this study is to assess if a higher dosage of topical minoxidil dosage (15%) will increase the number of responders among female subjects that have been identified through IVD testing as non-responders to 5% topical minoxidil.

NCT ID: NCT02393040 Active, not recruiting - Clinical trials for Androgenetic Alopecia

Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia

PRP
Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of treatment with Platelet-rich plasma on Androgenetic alopecia (compared with placebo), between six months and baseline.